Competitive Advantages

• Predicts the time of conversion from MCI to AD stage with 93.5% accuracy
• Computes 95% or 99% confidence limits of predicted conversion time
• Accurate Prediction Based on AI

Summary

Alzheimer’s Disease gradually degrades the memory of an individual over time.  The process cannot be reversed and there is no known cure.  In this technology, individuals with Mild Cognitive Impairment (MCI) are studied.  These patients are treated and observed to see if their MCI improves or deteriorates.  Some patients with MCI remain in that state, while other patients develop Alzheimer’s Disease.  Some patients may also revert back to Normal Cognition, but that is extremely rare.  This technology uses an artificial intelligence (AI) model created from data in the study to predict how long it takes for a patient with MCI to convert into the Alzheimer’s Disease stage.  The model will also determine risk factors, and interactions among the risk factors, that contribute to a conversion time of MCI to Alzheimer’s disease (AD).  While there is previous research on the subject, the novel aspect of this technology comes from the combination of prediction of the conversion time from MCI to AD in the patient and the determination of risk factors. In addition, this AI predictive analytical model can be used to evaluate the drug's effectiveness among other uses.

3-D image of brain atrophy differences in MCI patients and mild AD patients.

Desired Partnerships

• License
• Sponsored Research
• Co-Development